Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia

Author： Yood Marianne Ulcickas   Oliveria Susan A.   Cziraky Mark   Hirji Ishan   Hamdan Muhammad   Davis Catherine  

Publisher： Informa Healthcare

ISSN： 1473-4877

Source： Current Medical Research and Opinion, Vol.28, Iss.2, 2012-02, pp. : 213-219

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Comparing nilotinib with dasatinib as second-line therapies in patients with chronic myelogenous leukemia resistant or intolerant to imatinib - a retrospective chart review analysis

By Griffin James D.  

Current Medical Research and Opinion, Vol. 29, Iss. 6, 2013-06 ,pp. : 623-631

Informa Healthcare

Access to resources Recommend Favorite

Nilotinib Can Override Dasatinib Resistance in Chronic Myeloid Leukemia Patients with Secondary Resistance to Imatinib First-Line Therapy

By  

Acta Haematologica, Vol. 118, Iss. 3, 2007-09 ,pp. : 162-164

Karger

Access to resources Recommend Favorite

Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia

By Wu Eric Q.   Guerin Annie   Yu Andrew P.   Bollu Vamsi K.   Guo Amy   Griffin James D.  

Current Medical Research and Opinion, Vol. 26, Iss. 12, 2010-12 ,pp. : 2861-2869

Informa Healthcare

Access to resources Recommend Favorite

Dasatinib in the Treatment of Chronic Myeloid Leukemia

By  

Current Signal Transduction Therapy, Vol. 6, Iss. 1, 2011-01 ,pp. : 99-105

Bentham Science Publishers

Access to resources Recommend Favorite

Dasatinib for the treatment of chronic phase chronic myeloid leukemia

By Campbell Victoria   Copland Mhairi  

Clinical Practice, Vol. 10, Iss. 4, 2013-07 ,pp. : 415-425

Future Medicine

Access to resources Recommend Favorite